ECSP034600A - Compuestos de lactama - Google Patents

Compuestos de lactama

Info

Publication number
ECSP034600A
ECSP034600A EC2003004600A ECSP034600A ECSP034600A EC SP034600 A ECSP034600 A EC SP034600A EC 2003004600 A EC2003004600 A EC 2003004600A EC SP034600 A ECSP034600 A EC SP034600A EC SP034600 A ECSP034600 A EC SP034600A
Authority
EC
Ecuador
Prior art keywords
lactama
compounds
alaninyl
methylbutyryl
benzazepin
Prior art date
Application number
EC2003004600A
Other languages
English (en)
Inventor
Varghese John
Eugene D Thorsett
Jeffrey Nissen
Lee H Latimer
James E Audia
Jay S Tung
Stacey Leigh Mcdaniel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034600A publication Critical patent/ECSP034600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona el compuesto (N)- (S)-2-hidroxi-3- metilbutiril)-1- (l-alaninil) -(S)- 1-amino-3-metil-4, 5, 6, 7- tetrahidro-2H-3-benzazepin-2-ona.
EC2003004600A 2000-11-17 2003-05-13 Compuestos de lactama ECSP034600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
ECSP034600A true ECSP034600A (es) 2003-06-25

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004600A ECSP034600A (es) 2000-11-17 2003-05-13 Compuestos de lactama

Country Status (33)

Country Link
US (1) US20050261495A1 (es)
EP (1) EP1341531B1 (es)
JP (1) JP4116437B2 (es)
KR (1) KR100819679B1 (es)
CN (1) CN1486184A (es)
AR (1) AR035927A1 (es)
AU (2) AU4319202A (es)
BR (1) BR0115427A (es)
CA (1) CA2427227C (es)
CY (1) CY1106366T1 (es)
CZ (1) CZ20031351A3 (es)
DE (1) DE60126132T2 (es)
DK (1) DK1341531T3 (es)
DZ (1) DZ3453A1 (es)
EA (1) EA005954B1 (es)
EC (1) ECSP034600A (es)
ES (1) ES2278804T3 (es)
HR (1) HRP20030383B1 (es)
HU (1) HU228117B1 (es)
IL (2) IL155960A0 (es)
MX (1) MXPA03004292A (es)
MY (1) MY134559A (es)
NO (1) NO324324B1 (es)
NZ (1) NZ525854A (es)
PE (1) PE20020802A1 (es)
PL (1) PL212199B1 (es)
PT (1) PT1341531E (es)
SI (1) SI1341531T1 (es)
SK (1) SK288065B6 (es)
TW (1) TWI305204B (es)
UA (1) UA74849C2 (es)
WO (1) WO2002047671A2 (es)
ZA (1) ZA200303789B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2413705T3 (es) 2005-04-08 2013-07-17 Daiichi Sankyo Company, Limited Derivado de piridilmetilsulfona
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
JP5198877B2 (ja) * 2006-01-31 2013-05-15 株式会社エーピーアイ コーポレーション ベンゾアゼピノン類の製造方法
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
CA2693959A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
BRPI0815135A2 (pt) 2007-08-14 2015-02-03 Lilly Co Eli Derivados de azepina como inibidores de gama secretase.
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
CN105050598B (zh) 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
MX2021012690A (es) 2019-04-19 2022-01-31 Ligand Pharm Inc Formas cristalinas y metodos para producir formas cristalinas de un compuesto.
EP4076460B1 (en) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
JP7589247B2 (ja) 2019-12-17 2024-11-25 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｒｍｔ５阻害剤
GEAP202516720A (en) 2022-09-02 2025-07-10 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
IL320396A (en) 2022-10-25 2025-06-01 Merck Sharp & Dohme Llc Charge-linkers of anti-drug conjugates derived from extacan, pharmaceutical compositions, and uses thereof
US20240207425A1 (en) 2022-12-14 2024-06-27 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP970705A2 (en) * 1996-12-23 1998-10-31 Warren J. Porter CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING "beta" -AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
JP2002518481A (ja) * 1998-06-22 2002-06-25 エラン ファーマシューティカルズ，インコーポレイテッド β−アミロイドペプチドの放出および／またはその合成を阻害するための化合物
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ATE405577T1 (de) * 2000-11-17 2008-09-15 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung

Also Published As

Publication number Publication date
PT1341531E (pt) 2007-04-30
NZ525854A (en) 2004-06-25
IL155960A (en) 2009-06-15
SI1341531T1 (sl) 2007-06-30
IL155960A0 (en) 2003-12-23
PE20020802A1 (es) 2002-09-10
AU4319202A (en) 2002-06-24
HK1059731A1 (en) 2004-07-16
ZA200303789B (en) 2004-08-16
DK1341531T3 (da) 2007-05-14
KR100819679B1 (ko) 2008-04-04
HU228117B1 (en) 2012-11-28
AU2002243192B2 (en) 2006-07-20
AR035927A1 (es) 2004-07-28
SK5592003A3 (en) 2003-12-02
BR0115427A (pt) 2003-10-07
CY1106366T1 (el) 2011-10-12
EP1341531B1 (en) 2007-01-17
ES2278804T3 (es) 2007-08-16
MY134559A (en) 2007-12-31
EP1341531A2 (en) 2003-09-10
DE60126132D1 (de) 2007-03-08
TWI305204B (en) 2009-01-11
JP2004517090A (ja) 2004-06-10
NO20032236L (no) 2003-07-10
CZ20031351A3 (cs) 2003-11-12
CN1486184A (zh) 2004-03-31
DZ3453A1 (fr) 2002-06-20
WO2002047671A2 (en) 2002-06-20
KR20030051846A (ko) 2003-06-25
WO2002047671A3 (en) 2003-03-06
NO324324B1 (no) 2007-09-24
HRP20030383A2 (en) 2005-10-31
US20050261495A1 (en) 2005-11-24
HUP0301842A2 (hu) 2003-09-29
CA2427227C (en) 2010-08-17
HRP20030383B1 (hr) 2007-12-31
EA200300580A1 (ru) 2003-10-30
NO20032236D0 (no) 2003-05-16
DE60126132T2 (de) 2007-10-18
JP4116437B2 (ja) 2008-07-09
SK288065B6 (sk) 2013-04-03
PL212199B1 (pl) 2012-08-31
EA005954B1 (ru) 2005-08-25
HUP0301842A3 (en) 2010-03-29
PL362688A1 (en) 2004-11-02
MXPA03004292A (es) 2004-02-12
UA74849C2 (en) 2006-02-15
CA2427227A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
ECSP034600A (es) Compuestos de lactama
HN1999000154A (es) 1,2,3,4 tetrahidroquinolinas 2 sustituidas 4 - carboxiamino sustituidas.
NO20053246D0 (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
DE60135387D1 (de) 7,9 substituierte tetracyclinverbindungen
MY126559A (en) Fungicidal 2-methoxybenzophenones
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DE60225341D1 (de) Neue 1,2,4-triazolverbindung
ES2172864T3 (es) 2-metoxibenzofenonas fungicidas.
CY1106682T1 (el) Ενωση λακταμης
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
PT1389213E (pt) Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200100854A1 (ru) Кальций-литические соединения
GB9918429D0 (en) Organic compounds
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
DK1073447T3 (da) N1-modificerede glycopeptider
BR0205298B1 (pt) máquina de semeadura.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITTO20020747A1 (it) Composizione.
DE50214487D1 (de) Substituierte 1,5-diaminopentan-3-ol-verbindungen
ITTO20020745A1 (it) Composizione.
IT1303333B1 (it) Sottopiede per calzature.
ATE478155T1 (de) Glycopeptidantibiotika